Mistletoe therapy has gained global attention as a supportive treatment in cancer care. Developed from the Viscum album plant, this natural therapy is often used to enhance well-being, support the immune system, and improve tolerance to chemotherapy. ABNOBA GmbH, based in Pforzheim, Germany, is a trusted name in research-based mistletoe pharmaceuticals, with a long-standing commitment to safety and clinical efficacy.
Although mistletoe therapy is generally considered safe, it is important for patients to be informed about its potential side effects. Most reactions are mild and temporary. The most commonly reported effect is a localized skin reaction at the injection site — slight swelling, redness, or warmth — which usually indicates an expected immune response.
Some individuals may experience a low-grade fever or flu-like symptoms such as chills, fatigue, or muscle aches, especially during the first few weeks of therapy. These are typically signs of immune activation and often decrease as the body adjusts to treatment.
In rare cases, patients may encounter allergic reactions, including skin rash or shortness of breath. Hypotension (low blood pressure) or increased immune reactivity can also occur but are infrequent when therapy is properly supervised.
It is essential that mistletoe treatment is administered by trained professionals who can monitor dosage and patient response. ABNOBA’s standardized extracts offer reliable formulations that are clinically tested and used by integrative oncologists worldwide.
Patients should always discuss the risks and benefits with their healthcare provider to ensure a safe, personalized approach to mistletoe therapy.
